Vesber ,  An Innovative National High-tech Enterprise in High-end Ophthalmology

Vesber is a national high-tech enterprise focusing on the research and development, production and sales of innovative ophthalmic products.

Located in the core area of the Guangdong-Hong Kong-Macao Greater Bay Area – Guangdong Medical Valley Industrial Park, Nansha District, Vesber has class 10,000 clean workshop, Vesber Research Institute, Vesber Engineering Center, Clinical Training Center, etc., with a total of six floors and an area of more than 5,000 square meters.

Company Honor:

Since its establishment in 2007, Vesber has won the National 863 Project, the Twelfth Five-Year Support Plan, the SME Innovation Fund,Guangdong province industry-university-research and Guangzhou Science and Technology Program and supported by a series of government funds.

The representative product Foldable Capsular Vitreous Body (FCVB) obtained ISO13485 certification, EU CE certificate, Australian TGA registration certificate, And obtained the registration certificate of the State Food and Drug Administration(CFDA) through the innovation channel.

In 2013, FCVB was rated as one of the 4 advances in retinal detachment surgery in the world;

In 2015,FCVB was selected as “one of the top ten achievements in ophthalmology in China by the branch of the Chinese Medical Association;

In 2017,Vesber won the title of the first batch of high-tech enterprises in Guangdong Province;

In 2019, FCVB was awarded the “High-tech Products of Guangdong Province” in 2019;

In 2019, Vesber was awarded the 2019 Quality Credit Class A Medical Device Manufacturer in Guangdong Province;

In 2020, Vesber was awarded the title of National High-tech Enterprise twice;

In 2020, FCVB was selected into the third-level public hospital performance assessment and the fourth-level surgery catalog;

In 2021, FCVB was awarded as Guangdong famous high-tech product;

In 2021, the China Central Radio and Television Comprehensive Channel (CCTV-1) will report on the new technology “Artificial vitreous balloon to save the atrophied eyeball”;

In 2022, Xinhua News Agency reported “The Department of Ophthalmology of the People’s Liberation Army General Hospital conducts artificial vitreous balloon implantation”.

Main Products

Relying on the powerful R&D platform of Zhongshan Ophthalmology Center, Vesber researches and develops innovative ophthalmic products with a rigorous, scientific and responsible attitude.

The main products include Foldable Capsular Vitreous Body (FCVB), Foldable Capsular Buckle(FCB);High Myopic Posterior Scleral Fixation System(HM).

FCVB, the international first eyeball-saving artificial organ can mimic the structure and function of the vitreous body of the human eye to a subtle level and can stay in eyes for a long time. FVCB has been clinically applied in 200+ hospitals successful in the world, saving 2000+ patients with severe ocular trauma and oil-dependent eyes from the pain of of eyeball removal. Obtained 22 patents in China, the United States, Russia, Australia, Japan ect., FCVB has been carried out clinical application successfully in United Kingdom, Netherlands, Poland, Belgium, Greece, Russia, Australia, Turkey, Pakistan .

FCVB was was selected into the 2018 Medical Device Innovative Product Catalogue of the Ministry of Science and Technology of the People’s Republic of China, and was listed as a typical example of “Made in China” to “Created in China” by the State Food and Drug Administration in the review of the 40th anniversary of reform and opening up.

FCB is an innovative product for minimally invasive treatment of rhegmatogenous retinal detachment. Clinical research was launched in July 2019, and a total of 21 eye hospitals participated. The clinical research of this project and the launch of this product will bring new hope to the majority of patients with rhegmatogenous retinal detachment.

HM is developed by Vesber independently to delay the progression of myopia and treat posterior scleral staphyloma and retinoschisis caused by high myopia. At present, it has obtained the ethics review approval from Beijing Tongren Hospital and is conducting clinical trials in many hospitals.